How to Read FDA Advisory Committee (AdCom) Meeting Results

What Is an FDA Advisory Committee?

An FDA Advisory Committee (commonly called "AdCom") is a panel of independent experts convened by the FDA to review scientific data and provide non-binding recommendations on whether a drug should be approved. While the FDA isn't obligated to follow the committee's recommendation, it does so approximately 75-80% of the time.

Why AdCom Meetings Move Stock Prices

AdCom meetings are among the most volatile events in biotech because they provide the first public signal of how regulators view a drug. Key reasons:

Public vote: The committee votes yes/no on specific questions, creating a clear signal
Expert review: Panelists include leading physicians, statisticians, and patient advocates
Timing: AdCom meetings typically occur 1-3 months before the PDUFA date
FDA precedent: Historically, 75-80% of positive AdCom votes lead to FDA approval

How an AdCom Meeting Works

Before the Meeting

FDA briefing document: Published 1-2 days before the meeting. This is the FDA reviewer's analysis of the drug — a negative briefing document often signals trouble.
Company briefing document: The sponsor's presentation of their data.
Public comments: Patient advocacy groups and the public can submit statements.

During the Meeting

FDA presentation: FDA reviewers present their analysis
Company presentation: The sponsor presents their data and responds to FDA questions
Open public hearing: Patients and advocates share experiences
Panel discussion: Committee members discuss the data
Voting: The committee votes on specific questions posed by the FDA

The Vote

Typical voting questions include:

"Do the benefits of [drug] outweigh its risks for the proposed indication?"
"Has the applicant provided sufficient evidence of efficacy?"
"Is the safety profile acceptable?"

How to Interpret AdCom Results

Strong Positive (e.g., 12-1 or 10-2)

A lopsided positive vote is the strongest signal for approval. The FDA almost always follows strong positive recommendations.

Narrow Positive (e.g., 7-5 or 8-4)

A narrow positive vote creates uncertainty. The FDA may approve with additional restrictions or risk management requirements. Stock prices often remain volatile.

Negative Vote

A negative AdCom vote significantly reduces the probability of approval, but doesn't guarantee rejection. The FDA occasionally approves drugs despite negative AdCom recommendations, especially if:

The vote was close
There's a significant unmet medical need
Post-meeting data addresses committee concerns

No Vote / Discussion Only

Sometimes the FDA convenes an AdCom for discussion without a formal vote. These meetings are harder to interpret but can still provide signals through the tone of discussion.

Key Metrics to Watch

Vote margin: Larger margins are more predictive
FDA briefing document tone: Negative briefing documents correlate with negative outcomes
Questions asked: The specific questions the FDA poses can reveal their concerns
Panel composition: Check for conflicts of interest or domain expertise
Post-meeting FDA statements: Occasionally the FDA signals its interpretation

Historical Data

Positive AdCom → FDA Approval: ~75-80%
Negative AdCom → FDA Approval: ~15-25%
No AdCom convened → Generally positive signal (FDA is confident in its decision)

Tracking AdCom Meetings

AdCom meetings are publicly announced on the FDA's Federal Register notices and website. BioSniper aggregates these into a filterable calendar at biosniper.co/calendar/adcom, updated hourly.

Summary

FDA Advisory Committee meetings are critical catalysts for biotech investors. Understanding the process, reading briefing documents, and interpreting vote margins can give you an edge in evaluating the probability of drug approval.